Novo Nordisk stock weighs outlook boost against pricing pressure
Published on 11/06/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWegovy Pill Supports Novo's Recovery
- Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to a range of minus 2% to plus 2% at constant exchange rates.
- Third-quarter sales rose 4% at constant exchange rates to DKK 79.2 billion, while adjusted operating profit increased 27% to DKK 31.7 billion.
- Management expects the Wegovy pill to reach more than 20 markets by the first half of 2027, although pricing pressure and competition remain key risks.
Novo Nordisk raised its 2026 outlook on Wednesday, November 4, after third-quarter results and demand for its Wegovy pill exceeded expectations. The Danish drugmaker now expects adjusted sales and adjusted operating profit to range from a 2% decline to 2% growth at constant exchange rates, according to CNBC.
The revised outlook marks an improvement from the previous range of a 6% decline to flat growth for both measures. Novo said the change reflected stronger expectations for GLP-1 product sales, particularly in obesity care, while pricing pressure and intensifying competition continue to weigh on the business.
Wegovy Pill Leads Obesity Momentum
Third-quarter sales increased 4% at constant exchange rates to DKK 79.2 billion, ahead of FactSet expectations of DKK 73.6 billion. Adjusted operating profit reached DKK 31.7 billion, up 27% at constant exchange rates and above the expected DKK 28.6 billion.
Wegovy pill sales totaled DKK 5.4 billion in the quarter, compared with analyst expectations of roughly DKK 4.5 billion. Injectable Wegovy generated DKK 20.4 billion, while Ozempic sales reached DKK 29.7 billion. The company said the oral treatment had been launched in eight markets by early November and expects availability in more than 20 markets by the first half of 2027.
Chief Executive Mike Doustdar told CNBC that Wegovy maintained an 80% share of the oral obesity market in the United States. He also cautioned that one strong quarter was not enough to establish a full turnaround, leaving investors focused on whether prescription growth can remain durable as competition increases.
Pricing Pressure Remains Key Risk
The outlook assumes continued international growth but declining U.S. sales. Novo also faces lower realized prices linked to market-access investments and competitive pressure from Eli Lilly, whose obesity portfolio has gained ground in the United States.
Novo Nordisk stock traded at 35.87 euros on Lang & Schwarz at 11:37 CET on Friday, November 6, 2026. View the real-time quote of Novo Nordisk stock.
European pharmaceutical shares remain sensitive to obesity-drug pricing, prescription trends and pipeline news. Current Euro Stoxx 50 market reports provide broader market context.
More news and analyses on Novo Nordisk stock.
Novo Nordisk stock at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NVO
- Lang & Schwarz quote: 35.87 euros at 11:37 CET on November 6, 2026
- 2026 adjusted sales outlook: Minus 2% to plus 2% at constant exchange rates
- Third-quarter sales: DKK 79.2 billion, up 4% at constant exchange rates
- Third-quarter adjusted operating profit: DKK 31.7 billion, up 27% at constant exchange rates
